Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Kiora Pharmaceuticals is a clinical-stage biotech company focused on developing therapies for retinal diseases. Its core assets include KIO-301, a potential vision-restoring small molecule for retinitis pigmentosa, and KIO-104, an anti-inflammatory treatment for retinal conditions. The company advances its products through partnerships, proprietary IP, and clinical trials, targeting underserved ophthalmic markets with innovative, targeted therapies for vision loss and ocular inflammation.
This description was generated via AI from an annual report. Updated about 1 year ago.